{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:10:49Z","timestamp":1782979849588,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.conctc.2021.100855","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T12:06:02Z","timestamp":1636977962000},"page":"100855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Factors associated with successful phase III trials for solid tumors: A systematic review"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-0747","authenticated-orcid":false,"given":"Yasushi","family":"Otsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Narukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2021.100855_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2006.09.0803","article-title":"Economics of new oncology drug development","volume":"25","author":"DiMasi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2021.100855_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.conctc.2021.100855_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.conctc.2021.100855_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/clpt.2013.117","article-title":"Clinical approval success rates for investigational cancer drugs","volume":"94","author":"DiMasi","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.conctc.2021.100855_bib5","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-15-0124","article-title":"Failures in phase III: causes and consequences","volume":"21","author":"Seruga","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.conctc.2021.100855_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ctrv.2016.10.009","article-title":"Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review","volume":"52","author":"Jardim","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.conctc.2021.100855_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-019-00339-4","article-title":"First-line treatment of non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors","volume":"33","author":"Bylicki","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.conctc.2021.100855_bib8","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2021.100855_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jnci\/djv253","article-title":"Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval","volume":"107","author":"Jardim","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.conctc.2021.100855_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.conctc.2021.100855_bib12","first-page":"1","article-title":"Exploratory analysis of the factors associated with success rates of confirmatory randomized controlled trials in cancer drug development","author":"Wu","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.conctc.2021.100855_bib13","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of investigational drugs in late-stage clinical development and publication of trial results","volume":"176","author":"Hwang","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.conctc.2021.100855_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.279.4.281","article-title":"Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials","volume":"279","author":"Ioannidis","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.conctc.2021.100855_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001566","article-title":"Timing and completeness of trial results posted at clinicaltrials.gov and published in journals","volume":"10","author":"Riveros","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.conctc.2021.100855_bib16","first-page":"105","article-title":"Overcoming barriers to clinical trial enrollment, ASCO Edu","volume":"39","author":"Nipp","year":"2019","journal-title":"Book"},{"key":"10.1016\/j.conctc.2021.100855_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cct.2018.01.003","article-title":"Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative","volume":"66","author":"Huang","year":"2018","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.conctc.2021.100855_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(06)70576-9","article-title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-report factors","volume":"7","author":"Mills","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.conctc.2021.100855_bib19","author":"Food and Drug Administration"},{"key":"10.1016\/j.conctc.2021.100855_bib20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/cpt.1817","article-title":"Master, Master Key Project: powering clinical development for rare cancers through a platform trial","volume":"108","author":"Okuma","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.conctc.2021.100855_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jnci\/djv253","article-title":"Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval","volume":"107","author":"Jardim","year":"2015","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.conctc.2021.100855_bib22","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.conctc.2021.100855_bib23","article-title":"Biomarkers for personalized oncology: recent advances and future challenges","volume":"4","author":"Kalia","year":"2015","journal-title":"Metabolism"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:05:53Z","timestamp":1762520753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865421001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"alternative-id":["S2451865421001551"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100855","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with successful phase III trials for solid tumors: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100855"}}